[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":-5,"_23":24,"_25":26,"_27":28,"_29":30,"_31":30,"_32":33,"_34":35,"_36":37,"_38":39,"_40":41,"_42":43,"_44":45,"_46":-5,"_47":48,"_49":-5,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":41,"_58":41,"_59":60,"_61":41,"_62":63},"id","u27zeri0y7mnssmemwarjak46","revision",2,"title","Alnylam Pharmaceuticals 提交 8-K，公布截至 9 月 30 日的季度财务业绩","originalTitle","ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)","summary","Alnylam Pharmaceuticals 于 10 月 29 日宣布截至 9 月 30 日季度的财务业绩，并以 8-K 当前报告提交相关披露。完整新闻稿作为附件 99.1 随报告提供；文件未列出具体财务数据。","reason","source",{"_12":88,"_89":90,"_9":91,"_92":41,"_93":94,"_95":96},"links",{"_85":86,"_77":87},"publishedAt","2026-10-29T12:16:25.000Z","discoveredAt","2026-10-29T12:26:57.903Z","timelineAt","category","ai-products","tags",[82,83,84],"stockSymbols",[81],"score",24,"selected",true,"channel","news","story",{"_72":73,"_16":74},"x","readingMode","full","author","language","body",{"_63":76,"_77":-5,"_78":79,"_80":41},"outline",[],"relatedStories",[75],"indexable","markdownAvailable","group",{"_64":65,"_44":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","zh","factId","fIeDnKUoKg00",{"_72":73,"_16":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","aa42cbcc-c7bf-49b6-9681-28682301115c","Alnylam提交第三季度业绩披露",{"_72":73,"_16":74},"

美国

证券交易委员会

华盛顿特区 20549

___________________________________________

8-K表

___________________________________________

当前报告
根据第13条或第15(d)条

《1934年证券交易法》

报告日期（最早报告事件日期）：2026年10月29日

___________________________________________

Alnylam Pharmaceuticals, Inc.

___________________________________________

（注册人章程中指定的准确名称）


特拉华州	001-36407	77-0602661
（注册成立所在州或其他司法管辖区）	（委员会档案编号）	（美国国税局雇主识别号）

675 West Kendall Street,

Henri A. Termeer Square

马萨诸塞州剑桥

02142

（主要行政办公室地址）

（邮政编码）

注册人电话号码（含区号）：(617) 551-8200


不适用
（自上次报告以来如有变更的前名称或前地址）

___________________________________________

如果本8-K表申报旨在同时履行注册人在以下任何条款下的申报义务，请勾选相应方框（见下文一般说明A.2）：

☐ 根据《证券法》第425条（17 CFR 230.425）进行的书面通信

☐ 根据《交易法》第14a-12条（17 CFR 240.14a-12）进行的招揽材料

☐ 根据《交易法》第14d-2(b)条（17 CFR 240.14d-2(b)）进行的开始前通信

☐ 根据《交易法》第13e-4(c)条（17 CFR 240.13e-4(c)）进行的开始前通信

根据该法第12(b)条注册的证券：

各类证券名称

交易代码

注册所在交易所名称

普通股，每股面值$0.01

ALNY

纳斯达克股票市场有限责任公司

请勾选，以表明注册人是否属于《1933年证券法》第405条（本章§230.405）或《1934年证券交易法》第12b-2条（本章§240.12b-2）所定义的新兴成长型公司。

新兴成长型公司 ☐

如果属于新兴成长型公司，请勾选，以表明注册人是否选择不采用《交易法》第13(a)条规定的延长过渡期，以遵守任何新的或修订后的财务会计准则。 ☐

第2.02项。经营业绩和财务状况

2026年10月29日，Alnylam Pharmaceuticals, Inc.（“公司”）公布了截至2026年9月30日的季度财务业绩。与该公告相关发布的新闻稿全文作为附件99.1随本8-K表当前报告一并提交。

本 8-K 表格第 2.02 项中的信息（包括附件 99.1）不应被视为根据经修订的《1934 年证券交易法》（“《交易法》”）第 18 条“提交”，也不应受该条规定的责任约束；除非某项文件明确通过具体引用另有规定，否则也不应被视为通过引用纳入根据经修订的《1933 年证券法》或《交易法》提交的任何文件。

第 9.01 项。财务报表及附件

(d) 附件

以下与第 2.02 项相关的附件应视为已提供，而非已提交：

99.1 日期为 October 29, 2026 的新闻稿.

104 封面交互式数据文件（嵌入 Inline XBRL 文档中）。

签名


根据《1934 年证券交易法》的要求，注册人已正式授权下述签署人代表注册人签署本报告。

日期：October 29, 2026	ALNYLAM PHARMACEUTICALS, INC.

	签署人：	/s/ Jeffrey V. Poulton
		Jeffrey V. Poulton
		执行副总裁兼首席财务官

","original","zhKind","translation","complete","ALNY","公司与财报","财报","Nasdaq","aihot","/items/u27zeri0y7mnssmemwarjak46","https://www.sec.gov/Archives/edgar/data/1178670/000117867026000074/0001178670-26-000074-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1793664000&sig=2a69d6ab08599a1a","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1793664000&sig=c72c622a1dc90100 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1793664000&sig=c831626a2a361459 96w","changelogVersion","2026-10-01T08:00"]